Literature DB >> 3378430

Thiomersal allergy and vaccination reactions.

N H Cox1, A Forsyth.   

Abstract

Thiomersal is the preservative in all toxoid vaccines routinely administered to children in the UK, but exposure from other sources is uncommon. Delayed hypersensitivity to thiomersal was demonstrated in 1% of individuals attending the Contact Dermatitis Investigation Unit, and 50 of these patients with positive patch tests to thiomersal were studied. Cross-reaction with other mercurials occurred in 17 of 29 patients tested (59%). 31 of the patients replied to a questionnaire regarding vaccination reactions, and were compared with case-controls matched for age, sex, and site of dermatitis. 4 patients in each group reported reactions to vaccines which contained thiomersal, suggesting that thiomersal hypersensitivity was not associated with an increased risk of vaccination reactions. However, individual cases of severe reactions to thiomersal demonstrate a need for vaccines with an alternative preservative.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3378430     DOI: 10.1111/j.1600-0536.1988.tb02809.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  9 in total

1.  A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis.

Authors:  Royce Johnson; Steven M Kernerman; Bradley G Sawtelle; Suresh C Rastogi; H Stewart Nielsen; Neil M Ampel
Journal:  Mycopathologia       Date:  2012-06-06       Impact factor: 2.574

Review 2.  When should vaccination be contraindicated in children?

Authors:  Laura Lane; Arlene Reynolds; Mary Ramsay
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Immune-mediated adverse reactions to vaccines.

Authors:  Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2019-11-05       Impact factor: 4.335

Review 4.  Place of excipients in drug-related allergy.

Authors:  A Barbaud
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 5.  Vaccines without thiomersal: why so necessary, why so long coming?

Authors:  A J van't Veen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Thiomersal in vaccines: is removal warranted?

Authors:  C J Clements; L K Ball; R Ball; R D Pratt
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of tetanus.

Authors:  R Forrat; R Dumas; M Seiberling; M Merz; C Lutsch; J Lang
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 8.  Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease.

Authors:  Mark Bigham; Ray Copes
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 9.  Review: Vaccine Myth-Buster - Cleaning Up With Prejudices and Dangerous Misinformation.

Authors:  Paul Löffler
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.